BCR-ABL TARGETED THERAPIES ASSOCIATED WITH LEUKEMIA CHRONIC MYELOID (Atena Editora)

Abstract

Chronic myeloid leukemia (CML) occurs when the pluripotent stem cell undergoes a mutation that leads to clonal myelo-proliferation, generating an overproduction of mature and immature granulocytes. In 90% of CML cases, patients have the Ph+ Philadelphia chromosome, which represents a reciprocal translocation between chromosomes 9 and 22. Treatment for the comorbidity is performed with TKI tyrosine kinase inhibitors such as imatinib, nilotinib, bosutinib and ponatinib significantly improve response and prolong patient survival. This work is an integrative literature review developed according to the construction of the guiding question, literature search, data collection, categorization of selected studies, analysis, interpretation and discussion of results. In general, tyrosine kinase inhibitors have a similar principle of action, competing for the binding sites of the BCR-ABL enzyme with ATP, preventing prooncogenic activities; however, despite their promise, these drugs have hematological and non-hematological side effects. In view of this, challenges such as more accurate prognoses, safe dosage options and facing cases of multidrug resistance to standard therapy drugs. From the investigation of genetic characteristics combined with the use of sequencing technologies, such as predicting the course of the disease, they will have a greater probability of success.